A Unique Topoisomerase II Inhibitor with Dose-Affected Anticancer Mechanisms and Less Cardiotoxicity
Type II DNA topoisomerase (topo II) is an essential nuclear enzyme and a well-validated anticancer drug target. Previously, we have carried out several rounds of structural optimizations on our in-house topo II inhibitor <b>E17</b>, which was shown to have superior anticancer activity an...
Saved in:
Main Authors: | , , |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/e86a3e708ab4408d953393fc9792cecd |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|